|
Mar 17
|
30 Biggest Biotechnology Companies in the World
|
|
Mar 4
|
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
|
|
Feb 15
|
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
|
|
Jan 16
|
Vaxcyte Appoints Whitney Jones as Chief People Officer
|
|
Dec 21
|
Insider Sell: Vaxcyte Inc CFO Andrew Guggenhime Disposes of 8,000 Shares
|
|
Dec 8
|
We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely
|
|
Dec 4
|
VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
|
|
Nov 28
|
Vaxcyte Appoints Jacks Lee to Board of Directors
|
|
Nov 27
|
Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates
|
|
Sep 11
|
Codexis (CDXS) Transfers Leasing Rights to Vaxcyte, Stock Up
|
|
Sep 8
|
Peninsula biotech grabs more space as it plans to take 2nd pneumonia vaccine into clinic
|
|
Aug 8
|
Vaxcyte Reports Second Quarter 2023 Financial Results and Provides Business Update
|